{"id":"NCT01198327","sponsor":"Peter A Campochiaro, MD","briefTitle":"Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion","officialTitle":"Extended Follow-up of Patients With Macular Edema Due to bRanch rETinal Vein Occlusion (BRVO) or centrAl Retinal veIn occlusioN (CRVO) Previously Treated With Intravitreal Ranibizumab","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-08","primaryCompletion":"2012-12","completion":"2012-12","firstPosted":"2010-09-10","resultsPosted":"2014-01-13","lastUpdate":"2014-01-13"},"enrollment":66,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Retinal Vein Occlusion"],"interventions":[{"type":"DRUG","name":"ranibizumab","otherNames":["RBZ, lucentis"]},{"type":"OTHER","name":"Peripheral Laser","otherNames":["Laser"]}],"arms":[{"label":"Ranibizumab as needed","type":"EXPERIMENTAL"}],"summary":"This study evaluates long-term safety in patients with macular edema due to Retinal Vein Occlusion (RVO) originally enrolled in the BRAVO \\& CRUISE trials and subsequently followed in the HORIZON extension trial.","primaryOutcome":{"measure":"Incidence of Serious Adverse Events.","timeFrame":"24 mos","effectByArm":[{"arm":"Ranibizumab as Needed","deltaMin":17,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":6,"countries":["United States"]},"refs":{"pmids":["20630595","20398941"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":66},"commonTop":["Upper Respiratory Infection","Ocular discomfort","Subconjuctival Hemorrhage","Vitreous Hemmorhage"]}}